盐酸帕唑帕尼(pazopan ib hydrochloride)商品名为Votrient,由葛兰素史克公司(G laxoSm ithK line)研制开发。该药为口服制剂,2009年10月19日由美国食品药品管理局(FDA)宣布批准上市,用于晚期肾癌的治疗[1]。盐酸帕唑帕尼的中文化学名称:5-[[4-[(2,3-二甲基-2H-吲唑-6-基)甲氨 Pazopan ib hydrochloride is marketed as Votrient and was developed by GlaxoSmithKline. The drug is an oral formulation and was approved by the U.S. Food and Drug Administration (FDA) on October 19, 2009 for treatment of advanced renal cell carcinoma [1]. Chinese chemical name of pazopanib hydrochloride: 5 - [[4 - [(2,3-dimethyl-2H-indazol-6-yl) methanamine